Recombinant human interleukin 2 (IL-2), also known as aldesleukin, was the first immunomodulatory protein approved for cancer treatment (1). IL-2 therapy introduced a new perspective on cancer ...

The tumors that are not malignant, like hemangioma, are still a problem since they sometimes ulcerate and become infected and ...

Nonsteroidal anti-inflammatory drugs (NSAIDs), which play as COX-2 inhibitors, and EP antagonists are important in anti-tumor immune evasion. The COX-2-PGE2 pathway promotes tumor immune evasion by ...

Characterizing the tumor ... the immune response and avoid potential autoimmune-type damage following long-term antigen exposure, such as during chronic viral infections. 6 As of the time of ...

Our study thus confirmed what was found in people of African descent in the US: the genetic origin underpinning the excess ...

Excessive screen time and chronic stress, especially in young people, disrupt circadian rhythms and immune function, potentially increasing cancer risk. Screen exposure reduces melatonin ...

A new computer model will allow experts to identify specific immune ... lung cancer. This process, which spanned several years and cost millions of dollars, showed that immunotherapy-activated immune ...

A new human case of the bird flu has been confirmed in Nevada, and doctors are worried that it's a newer variant.

Computer Model Helps Identify Cancer-Fighting Immune Cells Key to Immunotherapy Feb. 3, 2025 — Researchers have developed a computer model to help scientists identify tumor-fighting immune cells ...

A team led by Dr. Manuel Serrano at IRB Barcelona has discovered a key strategy through which these persister cells evade the immune response and resist cancer treatments. Specifically ...

Jan. 15, 2025 — In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive ...